Next Article in Journal
Epigenetic DNA Modifications Upregulate SPRY2 in Human Colorectal Cancers
Next Article in Special Issue
Transfer of Cellular Content from the Allogeneic Cell-Based Cancer Vaccine DCP-001 to Host Dendritic Cells Hinges on Phosphatidylserine and Is Enhanced by CD47 Blockade
Previous Article in Journal
A Novel Likely Pathogenic Variant in the BLOC1S5 Gene Associated with Hermansky-Pudlak Syndrome Type 11 and an Overview of Human BLOC-1 Deficiencies
Previous Article in Special Issue
Enhancing a Natural Killer: Modification of NK Cells for Cancer Immunotherapy
 
 
Article

‘Off-the-Shelf’ Immunotherapy: Manufacture of CD8+ T Cells Derived from Hematopoietic Stem Cells

1
Cartherics Pty Ltd., Clayton, VIC 3168, Australia
2
Department of Obstetrics and Gynaecology, Monash University, Clayton, VIC 3168, Australia
*
Author to whom correspondence should be addressed.
Academic Editors: Francesca Patriarca and Cord Brakebusch
Cells 2021, 10(10), 2631; https://doi.org/10.3390/cells10102631
Received: 23 July 2021 / Revised: 11 September 2021 / Accepted: 24 September 2021 / Published: 2 October 2021
(This article belongs to the Special Issue Allogeneic Cell Cancer Immunotherapies)
Cellular immunotherapy is revolutionizing cancer treatment. However, autologous transplants are complex, costly, and limited by the number and quality of T cells that can be isolated from and expanded for re-infusion into each patient. This paper demonstrates a stromal support cell-free in vitro method for the differentiation of T cells from umbilical cord blood hematopoietic stem cells (HSCs). For each single HSC cell input, approximately 5 × 104 T cells were created with an initial five days of HSC expansion and subsequent T cell differentiation over 49 days. When the induced in vitro differentiated T cells were activated by cytokines and anti-CD3/CD28 beads, CD8+ T cell receptor (TCR) γδ+ T cells were preferentially generated and elicited cytotoxic function against ovarian cancer cells in vitro. This process of inducing de novo functional T cells offers a possible strategy to increase T cell yields, simplify manufacturing, and reduce costs with application potential for conversion into chimeric antigen receptor (CAR)-T cells for cancer immunotherapy and for allogeneic transplantation to restore immune competence. View Full-Text
Keywords: HSC; CD8+ T cells; differentiation; off-the-shelf immunotherapy HSC; CD8+ T cells; differentiation; off-the-shelf immunotherapy
Show Figures

Figure 1

MDPI and ACS Style

Boyd, N.; Cartledge, K.; Cao, H.; Evtimov, V.; Pupovac, A.; Trounson, A.; Boyd, R. ‘Off-the-Shelf’ Immunotherapy: Manufacture of CD8+ T Cells Derived from Hematopoietic Stem Cells. Cells 2021, 10, 2631. https://doi.org/10.3390/cells10102631

AMA Style

Boyd N, Cartledge K, Cao H, Evtimov V, Pupovac A, Trounson A, Boyd R. ‘Off-the-Shelf’ Immunotherapy: Manufacture of CD8+ T Cells Derived from Hematopoietic Stem Cells. Cells. 2021; 10(10):2631. https://doi.org/10.3390/cells10102631

Chicago/Turabian Style

Boyd, Nicholas, Kellie Cartledge, Huimin Cao, Vera Evtimov, Aleta Pupovac, Alan Trounson, and Richard Boyd. 2021. "‘Off-the-Shelf’ Immunotherapy: Manufacture of CD8+ T Cells Derived from Hematopoietic Stem Cells" Cells 10, no. 10: 2631. https://doi.org/10.3390/cells10102631

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop